Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail

B Pigneur, H Sokol, B Pigneur, H Sokol

Abstract

Inflammatory bowel disease (IBD) is due to an aberrant immune response toward luminal antigens, probably commensal bacteria, in genetically susceptible subjects and is also influenced by environmental factors. An imbalanced intestinal microbiota known as "dysbiosis," characterized by an increased proportion of pro-inflammatory microorganisms and a decreased proportion of anti-inflammatory microorganisms, has been repeatedly observed in IBD and is now recognized as a key factor in the gut inflammatory process. Fecal microbiota transplantation (FMT) has gained interest as a novel treatment option in IBD. The goal of FMT in IBD is not only to correct the dysbiosis, but also to restore a normal dialog between the host immune system and the microbiota. Data are still scarce, but the results of the first studies suggest that FMT could be a promising therapy in IBD. More studies are needed to define the best indications, optimal timing, frequency, mode of delivery, and the optimal donor for each patient.

References

    1. J Gastroenterol Hepatol. 2015 Jan;30(1):51-8
    1. Nature. 2014 May 15;509(7500):357-60
    1. Nature. 2011 Jun 15;474(7351):307-17
    1. Genome Biol. 2012 Apr 16;13(9):R79
    1. Gut Microbes. 2016 May 3;7(3):189-200
    1. Cell. 2007 Oct 5;131(1):33-45
    1. Science. 2016 Apr 29;352(6285):586-9
    1. FEMS Microbiol Ecol. 2004 Oct 1;50(1):25-36
    1. MBio. 2015 Apr 21;6(2):null
    1. Clin Infect Dis. 2011 Nov;53(10):994-1002
    1. J Transl Med. 2015 Sep 12;13:298
    1. Gastroenterology. 2012 Oct;143(4):913-6.e7
    1. J Pediatr Gastroenterol Nutr. 2013 Jun;56(6):597-601
    1. JAMA. 2014 Nov 5;312(17):1772-8
    1. Am J Gastroenterol. 2012 May;107(5):761-7
    1. BMC Microbiol. 2012 Jul 30;12:158
    1. Gut. 2016 Mar;65(3):415-25
    1. N Engl J Med. 2013 Jan 31;368(5):407-15
    1. Curr Opin Gastroenterol. 2010 Jul;26(4):327-31
    1. Cell. 2011 May 27;145(5):745-57
    1. Gastroenterology. 2015 Jul;149(1):102-109.e6
    1. Clin Infect Dis. 2015 Jul 1;61(1):136-7
    1. Therap Adv Gastroenterol. 2016 Mar;9(2):229-39
    1. Gut. 2006 Feb;55(2):205-11
    1. J Crohns Colitis. 2016 Apr;10(4):375-6
    1. Aliment Pharmacol Ther. 2014 May;39(10):1003-32
    1. Nature. 2014 Jun 19;510(7505):417-21
    1. Microbiome. 2015 Dec 17;3:75
    1. Clin Gastroenterol Hepatol. 2013 Aug;11(8):1036-8
    1. Open Forum Infect Dis. 2015 Feb 04;2(1):ofv004
    1. Am J Gastroenterol. 2013 Oct;108(10):1620-30
    1. Inflamm Bowel Dis. 2015 Mar;21(3):556-63
    1. Am J Gastroenterol. 2013 Apr;108(4):500-8
    1. J Crohns Colitis. 2014 Dec;8(12):1569-81
    1. Nature. 2014 Jan 23;505(7484):559-63
    1. Sci Rep. 2015 Aug 12;5:12955
    1. J Crohns Colitis. 2016 Apr;10 (4):387-94
    1. Gastroenterology. 2015 Jul;149(1):15-8
    1. N Engl J Med. 2015 Jul 16;373(3):287-8
    1. Gastroenterology. 2015 Jul;149(1):223-37
    1. J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):27-9
    1. Int J Colorectal Dis. 2016 May;31(5):1093-4
    1. Science. 2013 Feb 8;339(6120):708-11
    1. Cell Host Microbe. 2014 Mar 12;15(3):382-92
    1. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1433-8
    1. Inflamm Bowel Dis. 2009 Aug;15(8):1183-9
    1. Cell. 2006 Oct 20;127(2):423-33
    1. Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6
    1. Gastroenterology. 2015 Jul;149(1):110-118.e4
    1. JAMA. 2016 Jan 12;315(2):142-9

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren